Biomind Labs Inc. (BMNDF)
USD 0.7
(150.27%)
USD 0.7
(150.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.49 Million USD | 345.06% |
| 2022 | 336.72 Thousand USD | 0.53% |
| 2021 | 334.95 Thousand USD | 441.7% |
| 2020 | 61.83 Thousand USD | 18.57% |
| 2019 | 52.15 Thousand USD | -79.87% |
| 2018 | 259.01 Thousand USD | 26.95% |
| 2017 | 204.02 Thousand USD | -1.35% |
| 2016 | 206.81 Thousand USD | -21.84% |
| 2015 | 264.6 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.7 Million USD | 13.91% |
| 2024 Q2 | 1.9 Million USD | 11.6% |
| 2023 Q1 | 715.69 Thousand USD | 112.55% |
| 2023 Q3 | 1.27 Million USD | 17.86% |
| 2023 FY | 1.49 Million USD | 345.06% |
| 2023 Q2 | 1.08 Million USD | 51.39% |
| 2023 Q4 | 1.49 Million USD | 17.35% |
| 2022 Q2 | 107.87 Thousand USD | 2.12% |
| 2022 FY | 336.72 Thousand USD | 0.53% |
| 2022 Q4 | 336.72 Thousand USD | 9.73% |
| 2022 Q1 | 105.63 Thousand USD | -68.46% |
| 2022 Q3 | 306.85 Thousand USD | 184.45% |
| 2021 Q2 | 732.07 Thousand USD | 839.32% |
| 2021 FY | 334.95 Thousand USD | 441.7% |
| 2021 Q1 | 77.93 Thousand USD | 0.0% |
| 2021 Q4 | 334.95 Thousand USD | 7.57% |
| 2021 Q3 | 311.38 Thousand USD | -57.46% |
| 2020 FY | 61.83 Thousand USD | 18.57% |
| 2019 FY | 52.15 Thousand USD | -79.87% |
| 2018 FY | 259.01 Thousand USD | 26.95% |
| 2017 FY | 204.02 Thousand USD | -1.35% |
| 2016 FY | 206.81 Thousand USD | -21.84% |
| 2015 FY | 264.6 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -5362.808% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 84.168% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.932% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -85.29% |
| Rebus Holdings, Inc. | 5.24 Million USD | 71.411% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.461% |
| Qrons Inc. | 1.48 Million USD | -0.665% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -22.215% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.0% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3252.9% |
| Skye Bioscience, Inc. | 14.07 Million USD | 89.351% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.189% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 84.36% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -255.485% |
| SQZ Biotechnologies Company | 50.03 Million USD | 97.005% |
| Intellipharmaceutics International Inc. | 12 Million USD | 87.521% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 61.089% |
| Mesoblast Limited | 188.44 Million USD | 99.205% |
| Marizyme, Inc. | 26.67 Million USD | 94.382% |
| Genus plc | 485 Million USD | 99.691% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 74.35% |
| Pharming Group N.V. | 244.07 Million USD | 99.386% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 25.447% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 40.444% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 60.563% |
| ContraFect Corporation | 32.53 Million USD | 95.393% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 24.362% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 60.848% |
| IMV Inc. | 37.93 Million USD | 96.049% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 87.276% |
| MultiCell Technologies, Inc. | 1617.67 USD | -92540.155% |
| ONE Bio Corp. | 27.49 Million USD | 94.55% |
| Accustem Sciences Inc. | 1.07 Million USD | -38.858% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.064% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 29.146% |
| Q BioMed Inc. | 8.13 Million USD | 81.574% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.193% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 70.878% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.738% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 83.426% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 91.857% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -4.516% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -954.655% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -645.148% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 73.918% |
| GB Sciences, Inc. | 5.41 Million USD | 72.338% |
| Alpha Cognition Inc. | 7.16 Million USD | 79.084% |
| HST Global, Inc. | 593.59 Thousand USD | -152.465% |
| CSL Limited | 18.62 Billion USD | 99.992% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -19.014% |
| Halberd Corporation | 728.71 Thousand USD | -105.65% |
| Enzolytics Inc. | 365.26 Million USD | 99.59% |
| Agentix Corp. | 2.51 Million USD | 40.308% |
| Resverlogix Corp. | 67.39 Million USD | 97.776% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -78.676% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.663% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 12.566% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 93.944% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 87.41% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 59.112% |
| AVAX Technologies, Inc. | 3.99 Million USD | 62.476% |
| Zenith Capital Corp. | 27.56 Thousand USD | -5335.859% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.887% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -527.943% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 59.869% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -120.114% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 44.734% |
| Kadimastem Ltd | 3.5 Million USD | 57.242% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2139.107% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 97.019% |
| BioStem Technologies, Inc. | 15.9 Million USD | 90.578% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -222.491% |
| LadRx Corporation | 2.2 Million USD | 31.898% |
| Cell Source, Inc. | 15.8 Million USD | 90.519% |
| Regen BioPharma, Inc. | 5.45 Million USD | 72.541% |
| Regen BioPharma, Inc. | 5.45 Million USD | 72.541% |
| NovAccess Global Inc. | 7.86 Million USD | 80.935% |
| Affymax, Inc. | 8.87 Million USD | 83.107% |
| Itoco Inc. | 1.65 Million USD | 9.348% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 26.953% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 75.225% |
| Mobile Lads Corp. | 1.31 Million USD | -14.093% |
| CytoDyn Inc. | 127.89 Million USD | 98.828% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3485.282% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 4.326% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 86.432% |
| SYBLEU INC | 681.41 Thousand USD | -119.927% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 75.44% |
| International Stem Cell Corporation | 5.27 Million USD | 71.601% |
| Bioxytran, Inc. | 3.24 Million USD | 53.882% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -139.468% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 67.542% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 96.344% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 93.269% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 26.009% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 72.643% |
| Neutra Corp. | 973.52 Thousand USD | -53.936% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 94.835% |
| PureTech Health plc | 125.58 Million USD | 98.807% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 60.113% |
| IXICO plc | 1.9 Million USD | 21.138% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 92.7% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.55% |
| CSL Limited | 18.62 Billion USD | 99.992% |
| Cellectis S.A. | 249.36 Million USD | 99.399% |